Laboratory

Richmond Pharmacology’s laboratory is located in-house at our London Bridge site. It is operated by fully trained laboratory staff 24 hours a day and used for immediate sample processing needs.

The laboratories include refrigerated centrifuges for sample processing, refrigerators and -20°C and -80°C freezers for sample storage. The refrigerators and freezers are linked to an alarm system and the temperature is monitored continuously. Our laboratories also have a state-of-the-art, fully automated Drugs of Abuse (DOA) analyser, providing fast and accurate DOA results.

The Doctors Laboratory (TDL) is the central laboratory contracted by Richmond Pharmacology for the majority of studies Richmond Pharmacology are involved in. TDL is a fully CPA accredited laboratory that carries out regulatory compliant services on behalf of Richmond Pharmacology, including biochemistry, haematology, virology and microbiology. We offer a rapid turn around of routine, urgent and emergency results.

We have strong working relationships with numerous external laboratories, and through collaboration with these, Richmond Pharmacology can provide a comprehensive range of laboratory services. These services range from basic laboratory safety analyses to more extensive and complex testing requiring specialist techniques and equipment.

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more

Richmond Pharmacology listed in the J.P. Morgan Top 200 Female Powered Businesses

June 29, 2021
J.P. Morgan has identified Richmond Pharmacology as a high-growth female-powered business in its annual 'Top 200 Female Powered Businesses' list 2021.
Read more

CRISPR-Cas9 in-vivo gene editing shows reduction in TTR after a single dose

June 29, 2021
Data produced through Intellia Therapeutic’s NTLA-2001 FIH clinical trial, conducted at Richmond Pharmacology, indicates a reduction in the faulty TTR protein after a single infusion. Results were presented by Professor Julian Gillmore at this year’s Peripheral Nerve Society Annual Meeting.
Read more